The market for containment facilities and containment manufacturing will increase in the future, due to a growing demand for oncology treatments.
List view / Grid view
Filter the results
CPhI Worldwide will return for its 30th year on 5-7 November 2019 at Messe Frankfurt in Frankfurt, Germany.
GVOKE injection has received regulatory approval from the FDA for the treatment of severe hypoglycemia in patients with diabetes.
An import of medicinal cannabis from Portugal to Germany signifies the largest quantity ever moved within the EU, highlighting a surge in the medicinal cannabis products market.
The Operation Yellowhammer document has been published, which states that the UK will experience severe delays to the medical supply chain following a no-deal Brexit.
The lobbying group Innovative Medicines Canada has announced its lawsuit against plans to lower drug prices in the country.
The Kymriah (tisagenlecleucel) treatment has received a positive appraisal from the Scottish Medicines Consortium, after EMA approval last year.
Novartis reportedly knew of discrepancies in the Zolgensma data it had submitted to the FDA but delayed informing regulators so has announced alterations to its processes.
Generic treatments for blood/bone marrow disorders and acute nausea and vomiting associated with chemotherapy have gained FDA approval.
The biologic treatment ustekinumab has been granted an expanded use for ulcerative colitis within the EU.
Following positive clinical trials, the Tagrisso drug has been given marketing authorisation in China for treatment of NSCLC.
An annual report has found that the pharmaceutical sector is the lowest regarded industry among US citizens.
A ban on Indian trade to Pakistan has been partly changed to allow the import of drugs after a shortage of critical medicine.
The voretigene neparvovec gene therapy treatment has been highlighted in draft guidance by NICE for availability on the NHS.